Please login to the form below
Deal Watch table for May 2014
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during May 2014.
For an indepth analysis of these deals, read 'Pharma deals during May 2014'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Merck & Co OTC Business / Bayer | Asset / product acquisition | Consumer care business incl. Claritin, Afrin and Coppertone brands | 14,200 |
| CFR Pharmaceuticals / Abbott | Company acquisition | Chile-based branded generic company with Latin America (2013 sales $768m) | 3,330 |
| Bayer / Merck & Co | Co-development and co-commercialisation | Soluble guanylate cyclase modulators for cardiovascular disease | 2,100 |
| Valeant / Nestle | Asset / product acquisition | Injectable cosmetic fillers for facial wrinkles including Dysport | 1,400 |
| Ophthotech / Novartis | Commercialisation1 and co-development licence | Fovista (start p3) for treatment of wet age-related macular degeneration | 1,030 |
| Chelsea / Lundbeck | Company acquisition | US company with treatments for rare neurologic diseases | 658 |
| Avalanche / Regeneron | Development and commercialisation licence | Gene therapy products for ophthalmologic disease | 653 |
| Merck & Co / Santen | Asset / product acquisition2 | Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m | 600+ |
| MacroGenics / Takeda | Option to license end p1a to develop and commercialise | MGD010, a preclinical bispecific antibody for treatment of auto-immune disease | 502 |
| VersaPharm / Akorn | Company acquisition | US generic company selling dermatology products with $100m sales | 440 |
| Bayer Interventional Device Business / Boston Scientific | Asset / product acquisition | Devices for coronary and peripheral vascular disease (2013 sales $120m) | 415 |
| CytomX / BMS | Development and commercialisation licence | Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets | 348 |
| Bedford Labs (Boehringer Ingelheim) / Hikma | Asset / product acquisition | US generic injectable manufacturer and products (2013 sales $19m) | 300 |
| GSK product / Pernix | Asset / product acquisition3 | Marketed sumatriptan/naproxen combination. 2013 sales $79m | 267 |
| Lumena / Shire | Company acquisition | US company with late stage compounds for treatment of rare GI / hepatic diseases | 260+ |
| Xenoport / Reckitt Benckiser | Development and commercialisation licence | Arbaclofen placarbil end pIIa for alcohol use disorders | 145 |
| Neurotez / GCA Therapeutics | Development and commercialisation licence4 | Leptin derivatives for treatment of cognitive disorders | 103 |
| Fibrotech / Shire | Company acquisition | Australian company with pIb product for rare fibrotic kidney disease | 75+ |
| Ligand / Omthera (AstraZeneca) | Research, development and commercialisation licence | Omthera's prodrug delivery platform for omega-3 fatty acids for dyslipidaemia | 45 |
| Viking / Ligand | Licence to develop. Ligand provides $2.5m loan | Five development small molecule programmes. Lead product pIIb type 2 diabetes | N/D |
| AntiOp / Reckitt Benckiser | Supply and marketing agreement | Intranasal naloxone for opioid abuse in late clinical development | N/D |
All deals are worldwide unless otherwise noted.
1 - Ex-US
2 - Japan and key markets in Europe and Asia Pacific
3 - US
4 - China
Subscribe to our email news alerts
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- AstraZeneca and generative AI company Absci enter $247m oncology partnership
- EC approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy
- Global donors pledge over $777m to fight neglected tropical diseases at COP28 summit
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
No results were found
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
